A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer

Clinical trial NCT04069026 · COMPLETED

Trial details

NCT number: NCT04069026
Sponsor: Bayer
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumors

Start date: 2019-08-15
Primary completion: 2024-01-17
Enrollment: 78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.